Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells

BACKGROUND: Pirfenidone, a pleiotropic anti-fibrotic treatment, has been shown to slow down disease progression of idiopathic pulmonary fibrosis (IPF), a fatal and devastating lung disease. Rapamycin, an inhibitor of fibroblast proliferation could be a potential anti-fibrotic drug to improve the eff...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Pulm Med
Main Authors: Molina-Molina, M., Machahua-Huamani, C., Vicens-Zygmunt, V., Llatjós, R., Escobar, I., Sala-Llinas, E., Luburich-Hernaiz, P., Dorca, J., Montes-Worboys, A.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5922028/
https://ncbi.nlm.nih.gov/pubmed/29703175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-018-0626-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados